共 132 条
Emerging principles in protease-based drug discovery
被引:434
作者:
Drag, Marcin
[1
,2
]
Salvesen, Guy S.
[1
]
机构:
[1] Burnham Inst Med Res, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA
[2] Wroclaw Univ Technol, Fac Chem, Div Med Chem & Microbiol, PL-50370 Wroclaw, Poland
基金:
美国国家卫生研究院;
关键词:
MATRIX-METALLOPROTEINASE INHIBITORS;
M17 LEUCINE AMINOPEPTIDASE;
PEPTIDASE-IV INHIBITORS;
ANTHRAX LETHAL FACTOR;
ACTIVE-SITE;
SUBSTRATE-SPECIFICITY;
PEPTIDOMIMETIC INHIBITOR;
DEUBIQUITINATING ENZYMES;
COMBINATORIAL LIBRARIES;
NONPEPTIDIC INHIBITORS;
D O I:
10.1038/nrd3053
中图分类号:
Q81 [生物工程学(生物技术)];
Q93 [微生物学];
学科分类号:
071005 ;
0836 ;
090102 ;
100705 ;
摘要:
Proteases have an important role in many signalling pathways, and represent potential drug targets for diseases ranging from cardiovascular disorders to cancer, as well as for combating many parasites and viruses. Although inhibitors of well-established protease targets such as angiotensin-converting enzyme and HIV protease have shown substantial therapeutic success, developing drugs for new protease targets has proved challenging in recent years. This in part could be due to issues such as the difficulty of achieving selectivity when targeting protease active sites. This Perspective discusses the general principles in protease-based drug discovery, highlighting the lessons learned and the emerging strategies, such as targeting allosteric sites, which could help harness the therapeutic potential of new protease targets.
引用
收藏
页码:690 / 701
页数:12
相关论文